What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

EasyM

EasyM is a blood-based test for Multiple Myeloma minimal residual disease (MRD). The test is CLIA accredited, and not yet FDA approved.

04/10/2026

One day. One goal: Advancing the future of MRD 💪

We will be on the ground tomorrow in Miami for the myeloma MRD meeting! With a packed schedule, it’s going to be a milestone day for the community.

At EasyM, we are passionate about making MRD monitoring more accessible and patient-friendly through blood-based clonotypic mass spectrometry.

📩 DM us to set up a quick chat, we’d love to talk all things MRD with you!

04/09/2026

Major Milestone Announcement 📢

First Canadian prospective clinical study evaluating EasyM® for minimal residual disease (MRD) monitoring in multiple myeloma has completed patient enrollment.

Conducted in collaboration with Princess Margaret Cancer Centre (PMCC), this study explores a non-invasive, blood-based approach to tracking disease response in patients with newly diagnosed multiple myeloma (NDMM). By reducing reliance on bone marrow biopsies, EasyM® has the potential to make MRD testing more accessible, more frequent, and more patient-friendly, while maintaining high sensitivity and specificity.

MRD status is one of the strongest predictors of patient outcomes, and innovations like EasyM® could help enable more personalized, responsive treatment strategies, where therapy is adjusted based on more frequent disease monitoring.

We are deeply grateful to the patients, clinicians, and partners who made this milestone possible. Your participation and dedication are helping shape the future of multiple myeloma care.

Read the full announcement here: https://easym.com/rapid-novor-easym-multiple-myeloma-study-enrollment-complete/

04/02/2026

💡Non-secretory and oligosecretory multiple myeloma (MM) are often harder to detect, but they’re not identical:

Non-Secretory:
- Plasma cells don’t produce detectable M-protein at all
- Standard blood or urine tests may show nothing
- Monitoring relies on bone marrow biopsies & imaging

Oligosecretory:
- Plasma cells produce very low levels of M-protein
- Standard tests may miss it, even though disease is active
- Advanced tests like mass spectrometry can reveal hidden disease

Read more here: https://www.easym.com/types-of-multiple-myeloma/

03/31/2026

💡Did you know?

Not all multiple myeloma produces a complete M-protein.

In light chain only myeloma, malignant plasma cells produce only part of the antibody, called free light chains (kappa or lambda), instead of the full M-protein.

What makes it different?

- No intact (whole) M-protein
- Free light chains circulate rapidly and are cleared by the kidneys
- Standard monitoring can be more challenging

These free light chains can build up and cause kidney damage, making accurate detection critical.

Advanced mass spectrometry methods can detect and monitor light chain only disease, providing a sensitive, non-invasive way to track disease - even when traditional methods fall short.

Read more here: https://www.easym.com/types-of-multiple-myeloma/

03/19/2026

🚨 Early Detection in Multiple Myeloma After CAR-T Therapy!

A new study lead by Dr. Pasvolsky and colleagues at UT MD Anderson Cancer Center shows that EasyM, a blood-based clonotypic mass spectrometry-based assay, can track minimal residual disease (MRD) in multiple myeloma patients receiving Ciltacabtagene Autoleucel (cilta-cel) with unprecedented sensitivity.

Key Finding: EasyM spotted relapse 249 days before clinical progression, while traditional SPEP tests were still negative. This could help clinicians intervene earlier and tailor post-CAR-T monitoring.

This is the first study using EasyM in the post-CAR-T setting, and the results are promising for improving disease surveillance.

Read the full abstract: https://www.easym.com/mrd-monitoring-by-easym-in-multiple-myeloma-patients-receiving-ciltacabtagene-autoleucel/

03/16/2026

🩸 Who is at higher risk for multiple myeloma?

• Adults over 60
• Individuals of African Ancestry
• Men (slightly higher risk than women)
• People with a family history of blood cancers
• Those diagnosed with MGUS (a precursor condition)

Understanding these risk factors helps us advocate for earlier testing and monitoring, because knowledge is power. 💪

03/10/2026

🚨 Important news for Canadians living with multiple myeloma 🚨

For the first time, minimal residual disease (MRD) testing for multiple myeloma can be offered in Canada by a Canadian company for Canadian patients.

Rapid Novor’s EasyM® MRD blood test has received a provisional license from the Ontario Ministry of Health, allowing doctors to monitor the disease using a simple blood draw instead of repeated bone marrow biopsies.

Why this is important for patients:
• No painful bone marrow procedures
• Allows more frequent monitoring of the disease
• Can detect disease outside the bone marrow
• Easier testing logistics and more collection sites
• Better access for patients in rural and underserved communities

This is an important step toward improving how multiple myeloma is monitored across Canada.

🔗 Read the full announcement: https://www.easym.com/rapid-novors-blood-test-for-multiple-myeloma-mrd-monitoring-receives-moh-provisional-license/

03/07/2026

Know the CRAB symptoms of multiple myeloma:

🦀 C - Calcium elevation (high calcium levels)
🦀 R - Renal (kidney) problems
🦀 A - Anemia
🦀 B - Bone pain or bone damage

Learn more here: https://www.easym.com/types-of-multiple-myeloma/

Awareness saves lives 💛 Share to help spread awareness!

03/05/2026

What is Multiple Myeloma?

Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. When these cells become cancerous, they multiply uncontrollably, crowding out healthy blood cells and weakening the body’s ability to fight infection.

Myeloma cells can also cause bone damage and produce an abnormal protein called monoclonal protein (M-protein), which can harm the kidneys and interfere with normal immune function.

Early awareness can make a difference.

Learn the signs. Share the facts. 💛

Learn more here: https://www.easym.com/m-spike-and-multiple-myeloma/

03/03/2026

Myeloma Awareness Month is here 📣

This month, we’ll be sharing important myeloma facts to help raise awareness and support those affected by this cancer.

Follow along all month as we highlight key information and resources. Together, we can spread knowledge and hope 💪

02/28/2026

Frequently Asked Question: Blood Tests for Multiple Myeloma

💡What’s the difference between Clonotypic Mass Spectrometry and Blood-based Next Generation Sequencing (NGS)/Next Generation Flow (NGF)?

Clonotypic Mass Spec: Detects the abnormal protein (M-protein) myeloma cells make. Can find disease even if it’s hidden in the bone marrow or elsewhere.

Blood-based NGS/NGF: Detects cancer cells in circulating blood. Misses disease that is confined to the bone marrow, since myeloma cells don’t always enter the blood.

02/26/2026

How well does clonotypic mass spectrometry (CT-MS) align with next-generation flow (NGF) for measuring minimal residual disease (MRD) in multiple myeloma (MM)?

In Haematologica (Zhao et al., 2024), CT-MS blood-based MRD test was compared directly with EuroFlow (NGF) bone marrow-based MRD test.

Key findings:
• Blood-based CT-MS showed higher sensitivity than bone marrow/based EuroFlow (NGF)
• Rising CT-MS levels predicted relapse, up to 38 months earlier in some patients.
• Overall agreement was 72%, but MS+/NGF− discordance increased with deeper responses.
• CT-MS shows promise for non-invasive, sequential MRD monitoring in MM.

These results support an important concept: MRD assessment may not need to be confined to bone marrow.

Read the full study here: https://easym.com/comparison-of-easym-and-euroflow-mrd/

Address

EasyM C/o Rapid Novor Inc. , Unit 450, 137 Glasgow Street
Kitchener, ON
N2G4X8

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+18558999990

Website

http://www.easym.com/

Alerts

Be the first to know and let us send you an email when EasyM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to EasyM:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Kitchener?